
PLX
Protalix Biotherapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.530
Open
1.500
VWAP
--
Vol
455.91K
Mkt Cap
116.23M
Low
1.460
Amount
--
EV/EBITDA(TTM)
16.25
Total Shares
73.32M
EV
96.77M
EV/OCF(TTM)
--
P/S(TTM)
2.05
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
16.64M
-8.65%
--
--
17.72M
-0.64%
--
--
13.49M
+1.37%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Protalix BioTherapeutics, Inc. (PLX) for FY2025, with the revenue forecasts being adjusted by 5.09% over the past three months. During the same period, the stock price has changed by -52.44%.
Revenue Estimates for FY2025
Revise Upward

+5.09%
In Past 3 Month
Stock Price
Go Down

-52.44%
In Past 3 Month
1 Analyst Rating

927.40% Upside
Wall Street analysts forecast PLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLX is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy

927.40% Upside
Current: 1.460

Low
15.00
Averages
15.00
High
15.00

927.40% Upside
Current: 1.460

Low
15.00
Averages
15.00
High
15.00
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$10 → $15
2025-02-03
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10 → $15
2025-02-03
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Protalix Biotherapeutics Inc (PLX.A) is 6.25, compared to its 5-year average forward P/E of 0.57. For a more detailed relative valuation and DCF analysis to assess Protalix Biotherapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
0.57
Current PE
6.25
Overvalued PE
20.69
Undervalued PE
-19.55
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.42
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.33
Undervalued EV/EBITDA
-0.49
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
2.03
Current PS
1.76
Overvalued PS
3.18
Undervalued PS
0.87
Financials
Annual
Quarterly
FY2025Q1
YoY :
+169.82%
10.11M
Total Revenue
FY2025Q1
YoY :
-14.64%
-4.15M
Operating Profit
FY2025Q1
YoY :
-21.24%
-3.62M
Net Income after Tax
FY2025Q1
YoY :
-16.67%
-0.05
EPS - Diluted
FY2025Q1
YoY :
-249.42%
-5.36M
Free Cash Flow
FY2025Q1
YoY :
-37.51%
19.11
Gross Profit Margin - %
FY2025Q1
YoY :
-135.66%
-2.61
FCF Margin - %
FY2025Q1
YoY :
-70.81%
-35.79
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PLX News & Events
Events Timeline
2025-07-21 (ET)
2025-07-21
06:52:09
Protalix appoints Gilad Mamlok as CFO

2025-06-30 (ET)
2025-06-30
07:00:54
Protalix added to Russell 3000, Russell 2000 Indexes

2024-12-09 (ET)
2024-12-09
05:35:52
Protalix, Chiesi announce EMA validation of pegunigalsidase Variation Submission

Sign Up For More Events
Sign Up For More Events
News
5.0
07-21NASDAQ.COMProtalix BioTherapeutics Names Gilad Mamlok CFO
5.0
07-21NewsfilterProtalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
5.0
07-21SeekingAlphaProtalix BioTherapeutics appoints Gilad Mamlok as CFO
Sign Up For More News
People Also Watch

SRI
Stoneridge Inc
8.450
USD
-2.76%

TUSK
Mammoth Energy Services Inc
2.680
USD
-1.83%

PAYS
Paysign Inc
7.690
USD
-0.52%

CZWI
Citizens Community Bancorp Inc
14.790
USD
+0.14%

OGI
Organigram Global Inc
1.410
USD
-4.73%

FEIM
Frequency Electronics Inc
26.300
USD
-5.63%

BAER
Bridger Aerospace Group Holdings Inc
1.800
USD
-1.64%

GPRO
GoPro Inc
1.290
USD
-8.51%

PSQH
PSQ Holdings Inc
1.980
USD
-9.17%

PLBY
Playboy Inc
1.860
USD
0.00%
FAQ

What is Protalix Biotherapeutics Inc (PLX) stock price today?
The current price of PLX is 1.46 USD — it has decreased -2.67 % in the last trading day.

What is Protalix Biotherapeutics Inc (PLX)'s business?

What is the price predicton of PLX Stock?

What is Protalix Biotherapeutics Inc (PLX)'s revenue for the last quarter?

What is Protalix Biotherapeutics Inc (PLX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Protalix Biotherapeutics Inc (PLX)'s fundamentals?

How many employees does Protalix Biotherapeutics Inc (PLX). have?
